Matko Kalac

Title(s)Associate Clinical Professor, Medicine
SchoolSchool of Medicine
Address1001 Health Sciences Road
Irvine CA 92697-3950
vCardDownload vCard

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. N-quinoline-benzenesulfonamide derivatives exert potent anti-lymphoma effect by targeting NF-κB. iScience. 2020 Dec 18; 23(12):101884. Kalac M, Mangone M, Rinderspacher A, Deng SX, Scotto L, Markson M, Bansal M, Califano A, Landry DW, O'Connor OA. PMID: 33354662; PMCID: PMC7744703.
      View in: PubMed   Mentions:
    2. Acute cardiomyopathy following a single dose of doxorubicin in a patient with adult T-Cell leukemia/lymphoma. J Oncol Pharm Pract. 2021 Jun; 27(4):1011-1015. Farina K, Kalac M, Kim S. PMID: 32869692.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    3. Reversal of CYLD phosphorylation as a novel therapeutic approach for adult T-cell leukemia/lymphoma (ATLL). Cell Death Dis. 2020 02 05; 11(2):94. Xu X, Kalac M, Markson M, Chan M, Brody JD, Bhagat G, Ang RL, Legarda D, Justus SJ, Liu F, Li Q, Xiong H, Ting AT. PMID: 32024820; PMCID: PMC7002447.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansCells
    4. Brentuximab vedotin plus bendamustine in relapsed or refractory Hodgkin's lymphoma: an international, multicentre, single-arm, phase 1-2 trial. Lancet Oncol. 2018 02; 19(2):257-266. O'Connor OA, Lue JK, Sawas A, Amengual JE, Deng C, Kalac M, Falchi L, Marchi E, Turenne I, Lichtenstein R, Rojas C, Francescone M, Schwartz L, Cheng B, Savage KJ, Villa D, Crump M, Prica A, Kukreti V, Cremers S, Connors JM, Kuruvilla J. PMID: 29276022; PMCID: PMC9098158.
      View in: PubMed   Mentions: 36     Fields:    Translation:HumansCTClinical Trials
    5. A phase 1 study of romidepsin and pralatrexate reveals marked activity in relapsed and refractory T-cell lymphoma. Blood. 2018 01 25; 131(4):397-407. Amengual JE, Lichtenstein R, Lue J, Sawas A, Deng C, Lichtenstein E, Khan K, Atkins L, Rada A, Kim HA, Chiuzan C, Kalac M, Marchi E, Falchi L, Francescone MA, Schwartz L, Cremers S, O'Connor OA. PMID: 29141948; PMCID: PMC5790128.
      View in: PubMed   Mentions: 40     Fields:    Translation:HumansCTClinical Trials
    6. An Update on the Use of Immunotherapy in the Treatment of Lymphoma. Curr Hematol Malig Rep. 2017 08; 12(4):282-289. Marron TU, Kalac M, Brody J. PMID: 28735365.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    7. Brentuximab vedotin and bendamustine produce high complete response rates in patients with chemotherapy refractory Hodgkin lymphoma. Br J Haematol. 2018 03; 180(5):757-760. Kalac M, Lue JK, Lichtenstein E, Turenne I, Rojas C, Amengual JE, Sawas A, Deng C, Mapara MY, Connors JM, Kuruvilla J, O'Connor OA. PMID: 27984643.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    8. The combination of hypomethylating agents and histone deacetylase inhibitors produce marked synergy in preclinical models of T-cell lymphoma. Br J Haematol. 2015 Oct; 171(2):215-226. Marchi E, Zullo KM, Amengual JE, Kalac M, Bongero D, McIntosh CM, Fogli LK, Rossi M, Zinzani PL, Pileri SA, Piccaluga PP, Fuligni F, Scotto L, O'Connor OA. PMID: 26194163.
      View in: PubMed   Mentions: 20     Fields:    
    9. Propolis and its Active Component, Caffeic Acid Phenethyl Ester (CAPE), Modulate Breast Cancer Therapeutic Targets via an Epigenetically Mediated Mechanism of Action. J Cancer Sci Ther. 2013 Oct 21; 5(10):334-342. Omene C, Kalac M, Wu J, Marchi E, Frenkel K, O'Connor OA. PMID: 24466386; PMCID: PMC3898618.
      View in: PubMed   Mentions: 25  
    10. Sirtuin and pan-class I/II deacetylase (DAC) inhibition is synergistic in preclinical models and clinical studies of lymphoma. Blood. 2013 Sep 19; 122(12):2104-13. Amengual JE, Clark-Garvey S, Kalac M, Scotto L, Marchi E, Neylon E, Johannet P, Wei Y, Zain J, O'Connor OA. PMID: 23913470.
      View in: PubMed   Mentions: 33     Fields:    Translation:HumansAnimalsCellsCTClinical Trials
    11. Development and characterization of a novel CD19CherryLuciferase (CD19CL) transgenic mouse for the preclinical study of B-cell lymphomas. Clin Cancer Res. 2012 Jul 15; 18(14):3803-11. Scotto L, Kruithof-de Julio M, Paoluzzi L, Kalac M, Marchi E, Buitrago JB, Amengual J, Shen MM, O'Connor OA. PMID: 22589392.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansAnimalsCells
    12. HDAC inhibitors and decitabine are highly synergistic and associated with unique gene-expression and epigenetic profiles in models of DLBCL. Blood. 2011 Nov 17; 118(20):5506-16. Kalac M, Scotto L, Marchi E, Amengual J, Seshan VE, Bhagat G, Ulahannan N, Leshchenko VV, Temkin AM, Parekh S, Tycko B, O'Connor OA. PMID: 21772049; PMCID: PMC3217353.
      View in: PubMed   Mentions: 65     Fields:    Translation:HumansAnimalsCells
    13. [Autologous stem cell transplantation in patients with relapsed or refractory Hodgkin's disease]. Acta Med Croatica. 2009 Jun; 63(3):215-7. Minigo H, Vrhovac R, Kalac M, Jaksic B. PMID: 19827348.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    14. New drugs for the treatment of lymphoma. Hematol Oncol Clin North Am. 2008 Oct; 22(5):1007-35, x. Paoluzzi L, Kitagawa Y, Kalac M, Zain J, O'Connor OA. PMID: 18954749.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    15. A critical appraisal of conventional and investigational drug therapy in patients with hypereosinophilic syndrome and clonal eosinophilia. Cancer. 2007 Sep 01; 110(5):955-64. Kalac M, Quintás-Cardama A, Vrhovac R, Kantarjian H, Verstovsek S. PMID: 17654661.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCells
    16. [The disappearance of CD20 positive lymphocytes in the pleural effusion after intrapleural application of rituximab]. Acta Med Croatica. 2007 Sep; 61(4):425-7. Kalac M, Kolonic SO, Kardum-Skelin I, Planinc-Peraica A, Siftar Z, Jaksic B. PMID: 18044481.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    17. Central nervous system involvement of previously undiagnosed chronic lymphocytic leukemia in a patient with neuroborreliosis. Int J Hematol. 2007 May; 85(4):323-5. Kalac M, Suvic-Krizanic V, Ostojic S, Kardum-Skelin I, Barsic B, Jaksica B. PMID: 17483076.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCells
    18. [Microcellular lung carcinoma in patient with hepatosplenic T-cell lymphoma: a case report]. Lijec Vjesn. 2006 Mar-Apr; 128(3-4):76-8. Kalac M, Ostojic S, Gasparov S, Planinc-Peraica A, Dominis M, Jaksic B. PMID: 16808095.
      View in: PubMed   Mentions:    Fields:    Translation:Humans